Cardiogen (20mg)
$62.00
Cardiogen (20mg) is offered by Biotech Peptides for laboratory and analytical research. Also called AEDR, this four-amino-acid peptide has been studied in organotypic myocardial tissue cultures and experimental cardiac-injury models.pubmed.ncbi.nlm.nih+1
-
Product: Cardiogen
-
Alternative name: AEDR
-
Listed quantity: 20 mg
-
Reference sequence: H-Ala-Glu-Asp-Arg-OH
-
Intended use: Laboratory and analytical research only
Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.
For research use only. Not for human consumption.
Cardiogen (20mg) for Laboratory Research
Cardiogen (20mg) is offered by Biotech Peptides for laboratories investigating short-peptide biology, cardiac tissue cultures, and apoptosis-related research. Cardiogen is the tetrapeptide H-Ala-Glu-Asp-Arg-OH, commonly abbreviated AEDR.pubmed.ncbi.nlm.nih+1
For laboratories looking to buy Cardiogen, this listing identifies a 20 mg quantity. Confirm the supplied material’s sequence, terminal groups, chemical form, and analytical characteristics against the requirements of the intended work.
Explore our research peptides for sale to review other laboratory-use listings.
Cardiogen Product Information
| Property | Listing information |
|---|---|
| Product name | Cardiogen |
| Alternative name | AEDR |
| Listed quantity | 20 mg |
| Intended application | Laboratory and analytical research |
| Documentation inquiries | Include the product name and batch or lot number, where available |
The 20 mg designation describes the quantity stated for this listing. It does not independently establish net peptide content or confirm that a particular quantity-assay method has been performed.
Cardiogen Reference Molecular Characteristics
The following characteristics describe the unmodified Cardiogen reference structure. They are not analytical confirmation of an individual commercial batch.
| Reference characteristic | Information |
|---|---|
| Peptide length | Four amino acids |
| Amino-acid sequence | H-Ala-Glu-Asp-Arg-OH |
| One-letter sequence | AEDR |
| Chemical name | L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-L-arginine |
| Reference terminal groups | Free N-terminus and C-terminal carboxylic acid |
| Molecular formula | C₁₈H₃₁N₇O₉ |
| Approximate molecular weight | 489.5 g/mol |
| PubChem compound identifier | 11583989 |
The sequence, molecular formula, molecular weight, and terminal-group description are documented in the PubChem H-Ala-Glu-Asp-Arg-OH reference record. Confirm the supplied chemical form and any counterions against manufacturer specifications before using reference values in analytical calculations.
Cardiogen and Myocardial Tissue Research
A 2009 study by Chalisova and colleagues examined Cardiogen in organotypic myocardial tissue cultures from 3-month-old and 24-month-old rats. The investigators reported increased cell proliferation in both age groups at the studied concentration.
The same study reported decreased p53 protein expression by immunohistochemistry following Cardiogen exposure. The authors interpreted this as consistent with inhibition of apoptosis in myocardial tissue. These findings describe a specific tissue-culture model and do not establish clinical cardioprotection.
Read the primary myocardial tissue-culture study for the experimental methods and findings.
p53 and Apoptosis Context
p53 is a transcription factor involved in cell-cycle regulation, DNA-damage responses, and apoptosis. Reduced p53 expression in a tissue-culture model does not establish that Cardiogen prevents apoptosis, improves cardiac function, or treats heart disease in humans.pubmed.ncbi.nlm.nih+1
A separate study of human failing myocardium reported increased p53 expression and increased apoptosis in ventricular cardiomyocytes from patients with severe congestive heart failure. This provides biological context for p53-related research, but it does not establish that reducing p53 expression is beneficial in every cardiac setting.
Cardiac-Injury Research Context
A review of Cardiogen research describes a rat model of experimentally induced myocardial infarction in which Cardiogen exposure was associated with reduced mortality, reduced necrotic area, and preserved glycogen content in surviving myocardial tissue.
These findings apply to a specific rodent injury model and exposure conditions. They do not establish that Cardiogen treats myocardial infarction, heart failure, coronary artery disease, or any other cardiovascular condition in humans.biotechpeptides+1
Research Limitations
Published Cardiogen research examines organotypic tissue cultures, cell-based assays, and rodent injury models. It does not establish that Cardiogen treats heart failure, hypertension, angina, myocarditis, myocardial infarction, or any other condition.pubmed.ncbi.nlm.nih+2
Published research also does not verify the identity, purity, quantity, or biological activity of the commercial batch supplied with this listing.
Documentation and Batch Verification
Before selecting Cardiogen (20mg), review the information associated with the exact material being supplied. Depending on your protocol, relevant documentation may include:
-
Product name and batch or lot identifier.
-
Manufacturer specifications and chemical form.
-
Complete sequence and terminal-group information.
-
Counterion information, where applicable.
-
Identity-testing methods and reported results.
-
Purity-testing methods and supporting analytical data.
-
Quantity or peptide-content measurements, where required.
-
Product-specific storage and handling instructions.
Match identifiers across the label, specifications, and analytical reports. Obtain clarification if the documentation uses inconsistent names, sequences, or molecular values.
For inquiries, provide “Cardiogen (20mg),” the batch number where available, and the specific information your laboratory requires.
Storage and Handling
Follow the product-specific instructions supplied with the material and your laboratory’s applicable procedures.
Do not transfer storage temperatures, shelf-life claims, or preparation instructions from another supplier’s formulation or a differently modified peptide. Obtain clarification if documented instructions are unavailable or unclear.
Frequently Asked Questions About Cardiogen (20mg)
What is Cardiogen?
Cardiogen is the tetrapeptide H-Ala-Glu-Asp-Arg-OH, also abbreviated AEDR. It is a synthetic short peptide that has been studied in myocardial tissue-culture and rodent injury models.pubmed.ncbi.nlm.nih+1
Does Cardiogen reduce p53 expression?
The cited myocardial tissue-culture study reported decreased p53 protein expression by immunohistochemistry following Cardiogen exposure. This finding does not establish that a commercial batch reduces p53 expression in every biological system.
Does Cardiogen treat heart disease?
No. Published research is preclinical and does not establish treatment of heart failure, coronary artery disease, myocardial infarction, or any other cardiovascular condition.pubmed.ncbi.nlm.nih+2
What does the 20mg designation mean?
It is the quantity stated for this listing. It does not describe a concentration or independently establish net peptide content.
Does published research verify this product?
No. Publications describe the materials and conditions used by the investigators. Assess a commercial batch using relevant manufacturer specifications and analytical evidence.
Where can I find delivery information?
Review our shipping information for current order-processing and delivery terms.
Research Use Only
Cardiogen (20mg) is sold for laboratory and analytical research only. Not for human or animal consumption, personal administration, medical treatment, diagnosis, or veterinary application.
Review our Research-Use-Only Policy before ordering.
| Brand | Biotech Peptides |
|---|
Related products
Decapeptide-12 (200mg)
Decapeptide-12 (200mg), also known by its sequence YRSRKYSSWY, is a synthetic ten-amino-acid peptide investigated for its interaction with tyrosinase and its role in experimental melanogenesis research. Published studies have examined its effects on tyrosinase activity and melanin content in laboratory models. Listed for laboratory and analytical research.
FOXO4-DRI (Proxofim) (10mg)
FOXO4-DRI (Proxofim) (10mg) is offered by Biotech Peptides for laboratory and analytical research. FOXO4-DRI is a synthetic D-retro-inverso peptide, also called Proxofim, studied in relation to FOXO4-p53 signaling and senescent-cell apoptosis. 1241
-
Product: FOXO4-DRI
-
Alternative name: Proxofim
-
Listed quantity: 10 mg
-
Reference molecular formula: C₂₂₈H₃₈₈N₈₆O₆₄
-
Intended use: Laboratory and analytical research only
Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.
For research use only. Not for human consumption.
Melanotan 1 (10mg)
Melanotan 1 (10mg) is offered by Biotech Peptides for laboratory and analytical research. Also called afamelanotide, this synthetic 13-residue analogue of alpha-melanocyte-stimulating hormone has been studied in relation to melanocortin receptor signaling and melanin production.pmc.ncbi.nlm.nih+1
-
Product: Melanotan 1
-
Alternative name: Afamelanotide
-
Listed quantity: 10 mg
-
Reference molecular formula: C₇₈H₁₁₁N₂₁O₁₉
-
Intended use: Laboratory and analytical research only
Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.
For research use only. Not for human consumption.
Mod GRF 1-29 (CJC-1295 NO DAC) (5mg)
Mod GRF 1-29 (CJC-1295 NO DAC) (5mg) is offered by Biotech Peptides for laboratory and analytical research. Mod GRF 1-29 is a synthetic 29-residue GHRH analogue studied in relation to growth hormone-releasing hormone receptor signaling and somatotroph cell function. 1056
-
Product: Mod GRF 1-29
-
Alternative name: CJC-1295 without DAC
-
Listed quantity: 5 mg
-
Reference molecular formula: C₁₅₂H₂₅₂N₄₄O₄₂
-
Intended use: Laboratory and analytical research only
Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.
For research use only. Not for human consumption.
Pal-AHK (200mg) | Biotech Peptides
Pal-AHK (200mg) is listed as a palmitoylated AHK tripeptide for laboratory and analytical research. The supplied product description identifies the proposed structure as palmitoyl-Ala-His-Lys, combining an alanine-histidine-lysine peptide sequence with an N-terminal palmitoyl group.
Proposed reference characteristics (subject to manufacturer confirmation):- Listed quantity: 200mg
- Proposed peptide sequence: Ala-His-Lys (AHK)
- Proposed modification: N-terminal palmitoyl group
- Proposed molecular formula: C₃₁H₅₆N₆O₅
- Proposed molecular weight: Approximately 592.8 g/mol
TB-500 (Thymosin Beta-4) (10mg)
TB-500 (Thymosin Beta-4) (10mg) is offered by Biotech Peptides for laboratory and analytical research. TB-500 is a synthetic 43-residue peptide derived from thymosin beta-4, studied in relation to cell migration, angiogenesis, and wound-repair signaling. 1153
-
Product: TB-500
-
Full name: Thymosin Beta-4
-
Listed quantity: 10 mg
-
Reference molecular formula: C₂₁₂H₃₅₀N₅₆O₇₈S
-
Intended use: Laboratory and analytical research only
Review the manufacturer specifications and applicable analytical documentation before selecting material for your protocol.
For research use only. Not for human consumption.
